Factor V Leiden: A disorder of factor V anticoagulant function

Current Opinion in Hematology

Volumn 11, Issue 3, 2004, Pages 176-181

  Castoldi, Elisabetta ^a   Rosing, Jan ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Activated protein C cofactor; Activated protein C resistance; Anticoagulant factor V; Factor V leiden

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; PHOSPHOLIPID; PROTHROMBIN; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; ANTICOAGULATION; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CARBOXY TERMINAL SEQUENCE; CATALYSIS; GENE EXPRESSION; GENE MUTATION; HEMOSTASIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LINKAGE ANALYSIS; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVIEW; THROMBOSIS; TRANSGENE;

ACTIVATED PROTEIN C RESISTANCE; BLOOD COAGULATION; FACTOR V; HUMANS; POINT MUTATION; PROTEIN C; THROMBOPHILIA; THROMBOSIS; TIME FACTORS;

EID: 3242695796     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000130315.41033.32     Document Type: Review

References (44)

1. Dahlbäck B: The discovery of activated protein C resistance. J Thromb Haemost 2003, 1:3-9. An historical account of the APC resistance issue from the privileged viewpoint of the protagonist.
2. Nicolaes GA, Dahlbäck B: Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002, 22:530-538.
3. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993, 90:1004-1008.
4. Dahlbäck B, Hildebrand B: Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A 1994, 91:1396-1400.
5. Bertina RM, Koeleman BP, Koster T, et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
6. Zöller B, Dahlbäck B: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994, 343:1536-1538.
7. Shen L, Dahlbäck B: Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994, 269:18735-18738.
8. R506Q mutation, Thromb Haemost 1996, 76:208-214.
9. Váradi K, Moritz B, Lang H, et al.: A chromogenic assay for activated protein C resistance. Br J Haematol 1995, 90:884-891.
10. Thorelli E, Kaufman RJ, Dahlbäck B: Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999, 93:2552-2558.
11. Nicolaes GA, Tans G, Thomassen MC, et al.: Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995, 270:21158-21166.
12. Kalafatis M, Bertina RM, Rand MD, et al.: Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995, 270:4053-4057.
13. Rosing J, Hoekema L, Nicolaes GA, et al.: Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995, 270:27852-27858.
14. Heeb MJ, Kojima Y, Greengard JS, et al.: Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995, 85:3405-3411.
15. Castoldi E, Brugge JM, Nicolaes GA, et al.: Impaired APC-cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004, 103:in press. The role of the APC-cofactor activity of FV in APC resistance and in the regulation of thrombin generation in plasma is inferred from quantitative and functional FV defects: the first convincing evidence for the crucial pathophysiologic relevance of the anticoagulant activity of FV.
16. Simioni P, Girolami A: Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not. Blood Coagul Fibrinolysis 1994, 5:825-827.
17. Kalafatis M, Simioni P, Tormene D, et al.: Isolation and characterization of an anti-factor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood 2002, 99:3985-3992.
18. Henkens CM, Bom VJ, van der Meer J: Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995, 74:1198-1199.
19. Laffan MA, Manning R: The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996, 7:761-765.
20. Amano K, Michnick DA, Moussalli M, et al.: Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: implications for the APC resistance test. Thromb Haemost 1998, 79:557-563.
21. Hemker HC, Béguin S: Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995, 74:134-138.
22. Simioni P, Scudeller A, Radossi P, et al.: "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996, 75:422-426.
23. Castoldi E, Kalafatis M, Lunghi B, et al.: Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thromb Haemost 1998, 80:403-406.
24. Westrick RJ, Sun H, Eitzman DT, et al.: The factor V Leiden mutation results in the in vivo loss of a critical FV anticoagulant function [abstract]. Blood 2002, 100:127a.
25. Dahlbäck B, Villoutreix BO: Molecular recognition in the protein C anticoagulant pathway. J Thromb Haemost 2003, 1:1525-1534.
26. Lu D, Kalafatis M, Mann KG, et al.: Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996, 87:4708-4717.
27. Thorelli E, Kaufman RJ, Dahlbäck B: The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998, 273:16140-16145.
28. Kalafatis M, Rand MD, Mann KG: The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994, 269:31869-31880.
29. Rosing J, Bakker HM, Thomassen MC, et al.: Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993, 268:21130-21136.
30. 2 ratio do not fully explain R2-associated APC-resistance. Thromb Haemost 2002, 88:444-449.
31. Bernardi F, Faioni EM, Castoldi E, et al.: A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997, 90:1552-1557.
32. Castoldi E, Rosing J, Girelli D, et al.: Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000, 83:362-365.
33. Hoekema L, Castoldi E, Tans G, et al.: Functional properties of factor V and factor Va encoded by the R2-gene. Thromb Haemost 2001, 85:75-81.
34. Lunghi B, Iacoviello L, Gemmati D, et al.: Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996, 75:45-48.
35. Alhenc-Gelas M, Nicaud V, Gandrille S, et al.: The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999, 81:193-197.
36. de Visser MC, Guasch JF, Kamphuisen PW, et al.: The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000, 83:577-582.
37. Williamson D, Brown K, Luddington R, et al.: Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood 1998, 91:1140-1144.
38. Chan WP, Lee CK, Kwong YL, et al.: A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998, 91:1135-1139.
39. Norstrøm E, Thorelli E, Dahlbäck B: Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 2002, 100:524-530.
40. van der Neut Kolfschoten M, Dirven RJ, Tans G: et al.: The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model. Blood Coagul Fibrinolysis 2002, 13:207-215.
41. Steen M, Norstrøm EA, Tholander AL, et al.: Functional characterization of Factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood 2004, 103:3381-3387.
42. de Visser MC, Rosendaal FR, Bertina RM: A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999, 93:1271-1276.
43. Hemker HC, Béguin S: Phenotyping the clotting system. Thromb Haemost 2000, 84:747-751.
44. Fay PJ, Smudzin TM: Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem 1992, 267:13246-13250.